Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript [Seeking Alpha]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Seeking Alpha
Company Participants Vivian Wu - Investor Relations Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Mary Tagliaferri - Chief Medical Officer Conference Call Participants Jonathan Silverberg David Rosmarin Benjamin Ungar Julian Harrison - BTIG, LLC, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Jiale Song - Jefferies LLC, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Marc Frahm - TD Cowen, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division Yu Fan - Wedbush Securities Inc., Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Nektar Therapeutics Analyst and Investor event to discuss REZOLVE-AA 52-week top line results from the extension trea
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Announces Proposed Public OfferingPR Newswire
- NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & KorsinskyGlobeNewswire
- Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.MarketBeat
- Nektar Therapeutics (NKTR) had its price target raised by BTIG Research from $151.00 to $178.00. They now have a "buy" rating on the stock.MarketBeat
- NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
NKTR
Earnings
- 3/12/26 - Beat
NKTR
Sec Filings
- 4/20/26 - Form 8-K
- 4/17/26 - Form SCHEDULE
- 3/27/26 - Form SCHEDULE
- NKTR's page on the SEC website